1. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas
- Author
-
B Christoforov, Charikleia Kelaidi, François Dreyfus, F. Rollot, Sophie Park, Philippe Sogni, Yvon Calmus, Micheline Tulliez, Philippe Podevin, Didier Bouscary, and Philippe Blanche
- Subjects
Adult ,Male ,Cancer Research ,Lymphoma, B-Cell ,Hepacivirus ,Hepatitis C virus ,Alpha interferon ,Lymphoproliferative disorders ,medicine.disease_cause ,Antiviral Agents ,Virus ,chemistry.chemical_compound ,Ribavirin ,medicine ,Humans ,Prospective Studies ,Aged ,Retrospective Studies ,biology ,Interferon-alpha ,virus diseases ,Splenic lymphoma with villous lymphocytes ,Hematology ,Middle Aged ,biology.organism_classification ,medicine.disease ,Hepatitis C ,Virology ,digestive system diseases ,Lymphoma ,Treatment Outcome ,Oncology ,chemistry ,Immunology ,Drug Therapy, Combination ,Female - Abstract
A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.
- Published
- 2004
- Full Text
- View/download PDF